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Abstract: Endogenous insulin (UN) secreted by pancreatic β-cells plays a leading role in glucose 
homeostasis. Pathological changes in UN can enable early diagnosis of metabolic dysfunction before the 
emergence of type 2 diabetes. The dynamic insulin sensitivity and secretion test (DISST) is a dynamic test 
that is able to quantify participant-specific insulin sensitivity (SI) values and UN profiles. Like most 
studies, the DISST uses direct inversion of C-peptide concentration measurements to quantify a UN profile 
which relies on the assumption that insulin and C-peptide are equimolarly secreted from β-cells. This study 
develops a proportional-derivative (PD) control model that defines UN as a function of glucose 
concentration to provide further insight and modeling capability for this prediabetic state. Results show 
that individuals with normal glucose tolerance (NGT) tend to have higher gain ratio compared to 
individuals with impaired fasting glucose (IFG) with median values of 19.11 and 2.79 min, respectively. In 
particular, the main difference between the UN profiles of NGT and IFG group lies within the derivative 
gain (𝜙𝐷), specifically in first phase secretion (U1). A higher value of 𝜙𝐷 is needed in response to an 
abrupt increase in plasma glucose level. This proposed model offers model simplicity as well as a link 
between insulin secretion and glucose concentration that is able to provide more information in 
determining each participant’s glycemic condition.  
Keywords: Type 2 diabetes, Endogenous insulin secretion, Parameter identification, Insulin sensitivity, 
Closed-loop feedback-control system. 
 
1. INTRODUCTION 
Although the pathogenesis of type 2 diabetes (T2D) varies 
across individuals, typical pathogenesis includes the failure 
of the pancreatic β-cell to compensate for insulin resistance 
(IR) and the glucose load (Breda et al. 2002; Ferrannini 1997; 
Kahn 1998; Mari et al. 2002). The inability of β-cells to 
produce enough insulin to clear excess glucose results in high 
glucose concentrations in the blood. However, this elevation 
in blood glucose (BG) does not occur until insulin demand 
exceeds the maximal insulin secretion rate in the much later 
stages of the pathogenesis of type 2 diabetes, well after initial 
pathological changes in endogenous insulin secretion (UN) 
have occurred (Ferrannini 1997; Pories and Dohm 2012). 
Measuring endogenous insulin secretion may thus enable 
early diagnosis of metabolic dysfunction long before elevated 
BG occurs. Many studies have been conducted to determine 
the best technique for identifying endogenous insulin 
secretion (UN) by directly associating the insulin secretion 
with insulin sensitivity (Albareda et al. 2000; Bergman et al. 
2002; Lotz et al. 2010; McAuley et al. 2007). The gold 
standard, Euglycemic hyper-insulinaemic Clamp (EIC) 
(Defronzo et al. 1979) provides insulin sensitivity (SI = IR
-1
) 
by quantifying the glucose necessary to compensate for an 
increased insulin level by maintaining glucose concentration 
at a normal fasting concentration (typically ~4.6 mmol·L
-1
) 
(McAuley et al. 2001). However, the EIC does not provide 
UN characteristics and may thus miss early dysfunction.  
Unlike SI, there is no gold standard for β cell function or UN. 
Most secretion studies use deconvolution of C-peptide 
concentration measurements to identify the UN profile (Eaton 
et al. 1980; Polonsky et al. 1986; Van Cauter et al. 1992). 
This method is accurate because insulin and C-peptide are co-
secreted in an equimolar fashion from β cells (Rubenstein et 
al. 1969). However, accuracy can be compromised by low 
sampling frequency. In addition, insulin undergoes a 
substantial first pass hepatic extraction before reaching the 
peripheral circulation, which affects the ability to precisely 
predict UN directly from insulin measurements (Hovorka and 
Jones 1994; Polonsky and Rubenstein 1986). Thus, empirical 
or model-based methods that use C-peptide have proven a 
better means of UN quantification (Pacini and Mari 2003).  
The dynamic insulin sensitivity and secretion test (DISST) 
quantifies a patient-specific SI value and UN profile. The 
DISST SI value is highly correlated to the EIC (Rpearson = 
0.81), and the test can contrast UN characteristics across 
patient groups with different levels of IR (McAuley et al. 
2011). The DISST defines the patient-specific UN based on 
deconvolution of measured C-peptide data. However, these 
measurements are often relatively sparse. Hence, while 
  
 
     
diagnostically effective, there remains scope to reduce the 
sampling rate, and thus invasiveness and cost. 
Regulation of blood glucose by UN is effectively controlled 
by a closed-loop feedback-control system (Cherrington 
1999). Proportional-derivative (PD) control models have 
previously been proposed to link the defined patient-specific 
UN profile to glucose excursions. However, the main 
objective of this study is to further expand on the accuracy of 
this previously proposed PD control UN model in identifying 
and discriminating the UN profile for normal glucose 
tolerance (NGT) and impaired fasting glucose (IFG) 
participants in the presence of reduced data.  
2. METHODOLOGY 
2.1 Participants and Data 
A total of 94 female participants were recruited from the 
Otago region of New Zealand to take part in a 10-week 
dietary intervention trial defined in Te Morenga et al (2010). 
The median participant age was 42.5 years (IQR 34.5 – 50.5) 
and the median BMI was 32.34 kg/m
2
 (27.9 – 36.94) 
Inclusion criteria required a body mass index (BMI) greater 
than 25, or greater than 23 and a family history of T2D, or 
ethnic disposition toward T2D. Participants were excluded if 
they had a major illness, including established diabetes, at the 
time of testing. In total, 68 participants provided 204 full test 
DISST data sets at week 0, week 4 and week 10 of the 
intervention. 
2.2 Clinical Procedure 
Participants reported in the morning after at least 10 hours of 
overnight fasting. Each participant had a cannula inserted in 
the ante-cubital fossa (vein in inner elbow) for blood 
sampling and administration of glucose and insulin boluses. 
Blood samples were drawn at t=0, 5, 10, 15, 20, 25, 30, 35, 
40 and 50 minutes. A 10g IV glucose bolus (50% dextrose 
and 50% normal saline) was administered at t=6 minutes. 1U 
of IV insulin bolus was administered at t=16 minutes. Blood 
samples were assayed for plasma glucose (Enzymatic glucose 
hexokinase assay, Abbot Labs, Illinois USA), insulin and C-
peptide concentration (ELISA Immunoassay, Roche, 
Mannheim, Germany). 
2.3 Physiological Model 
2.3.1 DISST Model 
The DISST model provides quantitative measures of both SI 
and UN profile (Lotz et al. 2010; McAuley et al. 2011; 
McAuley et al. 2007), and was derived, in part, from the 
Minimal model of glucose dynamics (Bergman et al. 1979). 
The DISST model identifies the UN profile via the 
deconvolution of C-peptide assays (Van Cauter et al. 1992). 
The DISST model is defined:  
C-peptide Pharmaco-Kinetics: 
?̇? = −(𝑘1 + 𝑘3)𝐶 + 𝑘2𝑌 +
𝑈𝑁
𝑉𝑝
    (1) 
?̇? = −𝑘2𝑌 + 𝑘1𝐶     (2) 
Insulin Pharmaco-Kinetics: 
𝐼̇ = −𝑛𝑘𝐼 − 𝑛𝐿
𝐼
1+𝛼𝐼𝐼
−
𝑛𝐼
𝑉𝑝
(𝐼 − 𝑄) +
𝑈𝑒𝑥
𝑉𝑝
+ (1 − 𝑥𝐿)
𝑈𝑁
𝑉𝑝
 (3) 
?̇? = −(𝑛𝐶 +
𝑛𝐼
𝑉𝑞
)𝑄 +
𝑛𝐼
𝑉𝑞
𝐼    (4) 
and Glucose-Insulin Pharmaco-Dynamics: 
?̇? = −𝑝𝑔𝑢(𝐺 − 𝐺𝐵) − 𝑆𝐼(𝐺𝑄 − 𝐺𝐵𝑄𝐵) +
𝑃𝑡
𝑉𝑔
  (5) 
where equation nomenclature is shown in Table 1. 
Table 1. Nomenclature of the DISST model 
Variable Unit Description Role 
C pmol·L-1 
Plasma C-peptide 
concentration 
measured 
I mU·L-1 
Plasma insulin 
concentration 
measured 
G mmol·L-1 Blood glucose concentration measured 
Y pmol·L-1 
Interstitial C-peptide 
concentration 
simulated 
Q mU·L-1 
Interstitial insulin 
concentration 
simulated 
QB mU·L
-1 Basal interstitial insulin 
concentration 
simulated 
UN mU·min
-1 Endogenous insulin 
secretion  
simulated/ 
deconvoluted 
k1, k2, k3 min
-1 C-peptide transport rates a-priori 
Vp L 
Plasma insulin distribution 
volume 
a-priori 
Vq L 
Interstitial insulin 
distribution volume 
a-priori 
nk min
-1 Renal insulin clearance rate a-priori 
nI L·min
-1 Plasma-interstitial diffusion 
rate 
a-priori 
nC min
-1 Interstitial insulin 
degradation rate 
a-priori 
Uex mU·min
-1 Exogenous insulin input rate a-priori 
Pt 
mmol·min-
1 
Exogenous glucose input 
rate 
a-priori 
pgu min
-1 Non-insulin mediated 
glucose disposal rate 
a-priori 
αI L·mU
-1 Hepatic insulin clearance 
saturation parameter 
a-priori 
GB mmol·L
-1 Basal blood glucose 
concentration 
identified 
Vg L Glucose distribution volume identified 
nL min
-1 Hepatic insulin clearance 
rate 
identified 
xL 1 
Fractional first-pass hepatic 
insulin extraction 
identified 
SI 
L·mU-
1·min-1 
Insulin sensitivity identified 
2.3.2 PD UN model 
Regulation of blood glucose by insulin secretion is controlled 
by a physiological feedback-control system (Cherrington 
1999). Hence, a PD UN model was proposed to estimate UN 
as a function of increasing glucose (derivative control, 𝜙D) 
and glucose above basal (proportional control, 𝜙P). Since IV 
glucose is reasonably evenly distributed in blood plasma over 
10-15 minutes, time delays were not modelled in the 
coefficients of 𝜙D or 𝜙P. 
𝑈𝑁 = 𝑈𝐵 + 𝜙𝑃(𝐺 − 𝐺𝐵) + 𝜙𝐷〈?̇?〉   (6) 
  
 
     
where UN is the modelled endogenous insulin secretion 
[mU·min
-1
]; UB is basal insulin [mU·min
-1
]; 𝜙P and 𝜙D are 
the proportional, and derivative gains [mU·L·mmol
-1
·min
-1 
and mU·L·mmol
-1
, respectively]. Note that 〈?̇?〉 indicates the 
coefficient of 𝜙D is equal to zero if negative. UB is derived 
from Equations 1 and 2, assuming a steady state at t = 0 
minute: 
𝑈𝐵 = 𝑘3𝐶0𝑉𝑝     (7) 
where 𝐶0 denotes steady state C-peptide measured value at 
𝑡 = 0. 
2.4 Parameter Identification 
Initially, most of the a-priori parameters are quantified as 
functions of the participant anatomical characteristics 
(weight, height, sex, age) defined by Van Cauter et al. (Van 
Cauter et al. 1992). Typically, the DISST methodology sets 
pgu as a constant of 0.004 min
-1
 (Lotz et al. 2010). 
A seven parameter identification approach adapting the 
Gauss Newton method is developed to define the participant-
specific parameters of GB, SI, VG, 𝜙P, 𝜙D, nL and xL. The 
iterative function is defined: 
𝐱𝑖+1 = 𝐱𝑖 − (𝐉
𝐓𝐉)−1𝐉𝐓𝛙    (8) 
and minimises ‖𝛙‖2. 
where 𝐱i = [𝐺𝐵 , 𝑆𝐼𝑖 , 𝑉𝐺𝑖 , 𝜙𝐷𝑖 , 𝜙𝑃𝑖, 𝑛𝐿𝑖 , 𝑥𝐿𝑖] and i is the 
iteration number. The Jacobian matrix (J) and the residual 
matrix (ψ) are defined: 
𝐉(𝐱𝑖) =
[
 
 
 
 
 
𝛿𝜓1
𝛿𝐺𝐵
𝛿𝜓1
𝛿𝑆𝐼
⋯
𝛿𝜓1
𝛿𝑥𝐿
𝛿𝜓2
𝛿𝐺𝐵
𝛿𝜓2
𝛿𝑆𝐼
⋯
𝛿𝜓2
𝛿𝑥𝐿
⋮ ⋮ ⋱ ⋮
𝛿𝜓𝑛
𝛿𝐺𝐵
𝛿𝜓𝑛
𝛿𝑆𝐼
⋯
𝛿𝜓𝑛
𝛿𝑥𝐿 ]
 
 
 
 
 
   (8a) 
𝛙(𝐱i) = 
[
 
 
 
 
 
 
 
 
 
 
(𝐺(𝑥𝑖 , 𝑡1) − 𝐺𝑀,1) 𝐺𝑀̅̅ ̅̅⁄
⋮
(𝐺(𝑥𝑖 , 𝑡𝑛) − 𝐺𝑀,𝑛) 𝐺𝑀̅̅ ̅̅⁄
(𝐶(𝑥𝑖 , 𝑡1) − 𝐶𝑀,1) 𝐶𝑀̅̅ ̅̅⁄
⋮
(𝐶(𝑥𝑖 , 𝑡𝑛) − 𝐶𝑀,𝑛) 𝐶𝑀̅̅ ̅̅⁄
(𝐼(𝑥𝑖 , 𝑡1) − 𝐼𝑀,1) 𝐼?̅̅̅?⁄
⋮
(𝐼(𝑥𝑖 , 𝑡𝑛) − 𝐼𝑀,𝑛) 𝐼?̅̅̅?⁄ ]
 
 
 
 
 
 
 
 
 
 
   (8b)  
where I(xi,ts), G(xi,ts) and C(xi,ts) are the simulated values at t 
= ts given xi; IM,s, GM,s and CM,s are the measured values at t = 
ts (s=1..n); n is the number of measured samples; 𝐼?̅̅̅?, 𝐺𝑀̅̅ ̅̅  and 
𝐶𝑀̅̅ ̅̅  are the mean measured values of each measured species. 
To avoid model misidentification issues, insulin samples 
taken within 10 minutes of insulin administration and glucose 
samples taken within 10 minutes of glucose injection were 
ignored in the model fit to minimize errors introduced by 
variable effects of intravascular mixing (Caumo et al. 1999; 
Edsberg et al. 1987; Lotz 2007). VG is constrained within the 
range of 0.12Bw to 0.25Bw where bodyweight (Bw) is 
measured in kg and the coefficients have units of L·kg
-1
 
(Defronzo et al. 1979; Ferrannini and Mari 1998; Lotz 2007; 
Lotz et al. 2010). 
2.5 Statistics and Analysis 
In this study, the PD UN model accuracy was assessed via the 
produced residual matrix (ψ). The results of 𝜙P and 𝜙D are 
reported in median and interquartile range (IQR) for 3 patient 
categories: All, NGT, and IFG. All analyses were undertaken 
using MATLAB (R2013b, Mathworks, Inc., Natick, MA, 
USA). 
3. RESULTS 
Fig. 1 shows the simulated versus measured plasma insulin, 
glucose, C-peptide and UN profiles from one participant. Note 
again that the insulin and glucose samples taken within 10 
minutes of bolus injection were ignored due to unmodelled 
mixing effects. In general, using the DISST model with a PD 
UN model and a Gauss Newton identification method shows 
that the simulated data fits relatively very well against the 
measured data. 
Among 204 full DISST test data sets, 17 were classed as IFG 
based on a cut-off value of 5.56 mmol·L
-1
 (100 mg·dL
-1
 
(ADA 2012)) of fasting glucose (G0). Fig. 2 shows the 
distribution of 𝜙𝐷/𝜙𝑃 ratio against G0 across NGT and IFG 
group sets of data. It also shows that the median value of 
𝜙𝐷/𝜙𝑃 for NGT is higher than for IFG with 19.11 min and 
2.76 min, respectively.  
Fig. 3 shows the gain distribution of 𝜙D versus 𝜙P across 
both groups. It clearly shows that 𝜙D generates greater value 
than 𝜙P. A statistical summary of both gains are presented in 
Table 2 with ranksum and Kolmogorov-Smirnov significance 
values.   
Table 2. Summary statistics of derivative (𝝓D) and 
proportional (𝝓P) gains. 
 Median 
[IQR] 
Group 
ϕP 
 
ϕD 
 
ϕD
ϕP
 
NGT 
69.58 
[43.06, 96.41] 
1283.4 
[879.4, 1848.1] 
19.11 
[13.2, 27.6] 
IFG 
69.47 
[49.5, 100.1] 
302.55 
[25.72, 756.46] 
2.79 
[0.15, 13.25] 
pranksum 0.75 <0.0001 <0.0001 
pks 0.78 <0.0001 <0.0001 
 
  
 
     
 
Fig. 1: Simulated (solid blue line) and measured (red ‘+’ symbol) of; (A) plasma insulin, (B) glucose and (C) C-peptide for a 
typical participant response to the DISST model. (D) Endogenous insulin secretion profile identified from PD UN model (solid 
blue line) and from deconvoluted C-peptide measurement (solid green line). 
 
Fig. 2: Distribution of 𝜙𝐷/𝜙𝑃 against G0 where X = 19.11 
min and Y = 2.79 min. 
 
Fig. 3: Distribution of 𝜙D over 𝜙P during the intervention 
study. The 𝜙𝐷/𝜙𝑃 = 5, 10, and 100 dotted lines are shown for 
context. 
4. DISCUSSION 
The DISST validation study used deconvolution of C-peptide 
data to determine participant specific UN profiles (McAuley 
et al. 2011). However, regulation of blood glucose 
concentrations is effectively a closed-loop feedback-control 
system (Cherrington 1999). Hence, a proportional-derivative 
(PD) model is used that directly mimics this behaviour to 
identify a smoother, more physiological, UN profile. The 
main purpose of this study was to validate the PD UN model 
in differentiating NGT and IFG participants.  
The proposed PD UN model distinguishes UN profile into 3 
major roles; basal endogenous insulin secretion (UB), first 
phase insulin secretion and second phase insulin secretion. 
The derivative term (𝜙𝐷) determines the first phase of UN 
(U1) based on the dependence of insulin secretion on the 
positive rate of change of glucose concentration. The 
proportional term (𝜙𝑃) effectively determines the second 
phase of UN (U2) based on a proportional function over the 
basal glucose concentration at steady state level.  
Fig. 1 depicts the difference between identified UN from the 
PD UN model and the deconvoluted UN profile. It shows that 
the general trends of UN from the proposed PD UN model 
were in accordance with the deconvolved UN profile. 
Moreover, the proposed PD UN model provides a direct 
physiological link between glucose concentration and 
resultant insulin secretion, which is physiologically more 
accurate and provides a means to model this behaviour with 
limited data. Hence, the main benefit of the proposed model 
may be found when a lack of resolution in the C-peptide 
samples reduces accuracy of deconvolved UN profiles. 
Fig. 2 shows the distribution of 𝜙𝐷/𝜙𝑃 against fasting 
glucose (G0) on a log scale with the ADA guideline. It can be 
seen that the NGT group has higher gain ratio compared to 
IFG group where the median value of gain ratio was ~7× 
higher. Only 5 out of 187 NGT results are below the IFG 
median value showing clear separation. Theoretically, an 
individual with higher insulin resistance will have a limited 
first phase secretion, causing a much lower 𝜙𝐷/𝜙𝑃 ratio than 
a healthy participant with a high first phase insulin secretion. 
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Hence, the resultant difference in median ratios is somewhat 
expected across the NGT and IFG group. 
The pathogenesis of T2D progresses through 3 distinct 
stages: 1) normal glucose tolerance (NGT); 2) IFG and 
impaired glucose tolerance (IGT); and 3) T2D (Pories and 
Dohm 2012). IFG and IGT represent an intermediate 
metabolic state between normal glucose homeostasis and 
diabetes (Alberti and Zimmet 1998; Nathan et al. 2007). In 
general, determining the value of the derivative gain (𝜙𝐷) and 
proportional gain (𝜙𝑃) is crucial when assessing which stage 
the participant belongs to. Studies have shown that loss of 
first phase insulin secretion is an independent predictor of 
type 2 diabetes (Bunt et al. 2007; Del Prato and Tiengo 2001; 
Pratley and Weyer 2001; Vranic et al. 1971; Weyer et al. 
1999). In addition, second phase insulin secretion is an 
important characteristic in the prediabetic state (McAuley et 
al. 2011; Pories and Dohm 2012). In the model presented in 
the present study, this would be evident in a reduction in the 
value of 𝜙𝐷. Table 2 shows that 𝜙𝐷was significantly lower in 
the IFG subgroup of the cohort. Hence, the findings of this 
study are in agreement with previous studies. 
Fig. 3 shows that while 𝜙𝐷 gains are scattered across a wider 
range from ~0 to 4.93×10
3
 mU·L·mmol
-1
, 𝜙𝑃 remains at 
narrow range from 7.09 to 236.06 mU·L·mmol
-1
·min
-1
. In 
addition, Table 2 shows that although 𝜙𝑃 hold almost 
identical value across both group, 𝜙𝐷 remains significantly 
different between the NGT and IFG groups. Thus, it can be 
said that as 𝜙𝐷 decreases, the metabolic state moves from 
NGT toward the first known symptoms of diabetes. Fig. 3 
also shows this context with lines of 𝜙𝐷/𝜙𝑃  ratio 
discriminating different patient types for the most part. 
Hypothetically, while both gains play an important role in 
defining the participant-specific UN profile, it clearly shows 
that the comparatively important derivative gain, (𝜙𝐷) 
appears to be more important in defining the metabolic state 
of the participant. Clinically, IR participants relied more 
heavily on the second phase or proportional gain in 
maintaining the glucose homeostasis. This latter point was 
inferred by the diagnostic value of U2 in McAuley et al. 
(2011), and matches clinical expectations (Ferrannini 1997).  
If 𝜙𝑃 is fixed to a certain value, 𝜙𝐷 will vary when 
quantifying the participant-specific UN profile depending on 
the metabolic state of the participant. A value of 𝜙𝐷 ≈ 0 is 
predicted for participants with type 2 diabetes. Furthermore, 
down sampling measured glucose data when assessing UN 
characteristics over a limited period of time from 0 to 30 min 
will result in significantly reduced clinical cost and clinical 
attention during the trial. With fewer samples, the outcome 
result would provide less effective information compared to a 
full data set. However, further validation is needed to prove 
both assumptions and to determine the degree to which the 
findings of this study can be interpolated in a down-sampling 
exercise.  
While this PD control UN model requires further validation, it 
is likely to be useful for analysis of the pathogenesis of T2D 
as it captures the physiological determinants of participant-
specific UN profiles. This model provides a direct 
physiological link between insulin secretion to glucose 
concentration as well as insulin sensitivity. 
5. CONCLUSIONS 
This study presented a thorough analysis of proportional-
derivative model of insulin secretion adapting a Gauss 
Newton parameter identification method. The proposed 
model offers model simplicity as well as a link between 
insulin secretion and glucose concentration. In addition, it 
provides more information in determining the condition stage 
of each participant. 
ACKNOWLEDGEMENT 
The authors wish to thank Dr Lisa Te Morenga, Prof. Jim 
Mann and Dr Kirsten McAuley for providing the clinical data 
used in this analysis. 
REFERENCES 
ADA (2012) Diagnosis and classification of diabetes 
mellitus, Diabetes Care, 35 Suppl 1(S64-71 
Albareda M., Rodriguez-Espinosa J., Murugo M., de Leiva 
A., Corcoy R. (2000) Assessment of insulin sensitivity 
and beta-cell function from measurements in the fasting 
state and during an oral glucose tolerance test, 
Diabetologia, 43(12), 1507-1511 
Alberti K.G., Zimmet P.Z. (1998) Definition, diagnosis and 
classification of diabetes mellitus and its complications. 
Part 1: diagnosis and classification of diabetes mellitus 
provisional report of a WHO consultation, Diabet Med, 
15(7), 539-553 
Bergman R., Ider Y., Bowden C., Cobelli C. (1979) 
Quantitative estimation of insulin sensitivity, Am J 
Physiol, 236(E667 - 677 
Bergman R.N., Finegood D.T., Kahn S.E. (2002) The 
evolution of beta-cell dysfunction and insulin resistance 
in type 2 diabetes, Eur J Clin Invest, 32 Suppl 3(35-45 
Breda E., Toffolo G., Polonsky K.S., Cobelli C. (2002) 
Insulin release in impaired glucose tolerance: oral 
minimal model predicts normal sensitivity to glucose but 
defective response times, Diabetes, 51 Suppl 1(S227-233 
Bunt J.C., Krakoff J., Ortega E., Knowler W.C., Bogardus C. 
(2007) Acute insulin response is an independent predictor 
of type 2 diabetes mellitus in individuals with both 
normal fasting and 2-h plasma glucose concentrations, 
Diabetes-Metabolism Research and Reviews, 23(4), 304-
310 
Caumo A., Vicini P., Zachwieja J.J., Avogaro A., Yarasheski 
K., Bier D.M., Cobelli C. (1999) Undermodeling affects 
minimal model indexes: insights from a two-compartment 
model, Am J Physiol, 276(6 Pt 1), E1171-1193 
Cherrington A.D. (1999) Banting Lecture 1997. Control of 
glucose uptake and release by the liver in vivo, Diabetes, 
48(5), 1198-1214 
  
 
     
Defronzo R.A., Tobin J.D., Andres R. (1979) Glucose Clamp 
Technique - Method for Quantifying Insulin-Secretion 
and Resistance, American Journal of Physiology, 237(3), 
E214-E223 
Del Prato S., Tiengo A. (2001) The importance of first-phase 
insulin secretion: implications for the therapy of type 2 
diabetes mellitus, Diabetes-Metabolism Research and 
Reviews, 17(3), 164-174 
Eaton R.P., Allen R.C., Schade D.S., Erickson K.M., 
Standefer J. (1980) Prehepatic Insulin Production in Man 
- Kinetic-Analysis Using Peripheral Connecting Peptide 
Behavior, Journal of Clinical Endocrinology & 
Metabolism, 51(3), 520-528 
Edsberg B., Herly D., Hildebrandt P., Kuhl C. (1987) Insulin 
bolus given by sprinkler needle: effect on absorption and 
glycaemic response to a meal, Br Med J (Clin Res Ed), 
294(6584), 1373-1376 
Ferrannini E. (1997) Insulin resistance is central to the 
burden of diabetes, Diabetes Metab Rev, 13(2), 81-86 
Ferrannini E., Mari A. (1998) How to measure insulin 
sensitivity, Journal of Hypertension, 16(7), 895-906 
Hovorka R., Jones R.H. (1994) How to Measure Insulin-
Secretion, Diabetes-Metabolism Reviews, 10(2), 91-117 
Kahn B.B. (1998) Type 2 diabetes: when insulin secretion 
fails to compensate for insulin resistance, Cell, 92(5), 
593-596 
Lotz T.F.: High resolution clinical model-based assessment 
of insulin sensitivity. In Department of Mechanical 
Engineering, University of Canterbury, New Zealand, 
2007 
Lotz T.F., Chase J.G., McAuley K.A., Shaw G.M., Docherty 
P.D., Berkeley J.E., Williams S.M., Hann C.E., Mann J.I. 
(2010) Design and Clinical Pilot Testing of the Model-
Based Dynamic Insulin Sensitivity and Secretion Test 
(DISST), J Diabetes Sci Technol, 4(6), 1408-1423 
Mari A., Tura A., Gastaldelli A., Ferrannini E. (2002) 
Assessing insulin secretion by modeling in multiple-meal 
tests: role of potentiation, Diabetes, 51 Suppl 1(S221-226 
McAuley K.A., Berkeley J.E., Docherty P.D., Lotz T.F., 
Morenga L.A.T., Shaw G.M., Williams S.M., Chase J.G., 
Mann J.I. (2011) The dynamic insulin sensitivity and 
secretion test-a novel measure of insulin sensitivity, 
Metabolism-Clinical and Experimental, 60(12), 1748-
1756 
McAuley K.A., Mann J.I., Chase J.G., Lotz T.F., Shaw G.M. 
(2007) Point: HOMA - Satisfactory for the Time Being: 
HOMA: the best bet for the simple determination of 
insulin sensitivity, until something better comes along, 
Diabetes Care, 30(9), 2411-2413 
McAuley K.A., Williams S.M., Mann J.I., Walker R.J., 
Lewis-Barned N.J., Temple L.A., Duncan A.W. (2001) 
Diagnosing insulin resistance in the general population, 
Diabetes Care, 24(3), 460-464 
Morenga L.T., Williams S., Brown R., Mann J. (2010) Effect 
of a relatively high-protein, high-fiber diet on body 
composition and metabolic risk factors in overweight 
women, Eur J Clin Nutr, 64(11), 1323-1331 
Nathan D.M., Davidson M.B., DeFronzo R.A., Heine R.J., 
Henry R.R., Pratley R., Zinman B. (2007) Impaired 
fasting glucose and impaired glucose tolerance - 
Implications for care, Diabetes Care, 30(3), 753-759 
Pacini G., Mari A. (2003) Methods for clinical assessment of 
insulin sensitivity and beta-cell function, Best Pract Res 
Clin Endocrinol Metab, 17(3), 305-322 
Polonsky K., Rubenstein A. (1986) Current approaches to 
measurement of insulin secretion, Diabetes Metab Rev, 
2(3‐4), 315-329 
Polonsky K.S., Liciniopaixao J., Given B.D., Pugh W., Rue 
P., Galloway J., Karrison T., Frank B. (1986) Use of 
Biosynthetic Human C-Peptide in the Measurement of 
Insulin-Secretion Rates in Normal Volunteers and Type-I 
Diabetic-Patients, Journal of Clinical Investigation, 
77(1), 98-105 
Pories W.J., Dohm G.L. (2012) Diabetes: Have We Got It All 
Wrong?: Hyperinsulinism as the culprit: surgery provides 
the evidence, Diabetes Care, 35(12), 2438-2442 
Pratley R.E., Weyer C. (2001) The role of impaired early 
insulin secretion in the pathogenesis of Type II diabetes 
mellitus, Diabetologia, 44(8), 929-945 
Rubenstein A.H., Clark J.L., Malani F., Steiner D.F. (1969) 
Secretion of Proinsulin C-Peptide by Pancreatic Beta 
Cells and Its Circulation in Blood, Nature, 224(5220), 
697-& 
Van Cauter E., Mestrez F., Sturis J., Polonsky K.S. (1992) 
Estimation of insulin secretion rates from C-peptide 
levels. Comparison of individual and standard kinetic 
parameters for C-peptide clearance, Diabetes, 41(3), 368-
377 
Vranic M., Fono P., Kovacevi.N, Lin B.J. (1971) Glucose 
Kinetics and Fatty Acids in Dogs on Matched Insulin 
Infusion after Glucose Load, Metabolism-Clinical and 
Experimental, 20(10), 954-& 
Weyer C., Bogardus C., Mott D.M., Pratley R.E. (1999) The 
natural history of insulin secretory dysfunction and 
insulin resistance in the pathogenesis of type 2 diabetes 
mellitus, Journal of Clinical Investigation, 104(6), 787-
794 
 
